Abstract
Alzheimer's disease (AD) is characterized by several pathologies, this disease is a neuropathological lesion in brain. Indeed, a wealth of evidence suggests that β-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. AD is the most prevalent form of dementia, and current indications show that twenty-nine million people live with AD worldwide, a figure expected rise exponentially over the coming decades. Clearly, blocking disease progression or, in the best-case scenario, preventing AD altogether would be of benefit in both social and economic terms. However, current AD therapies are merely palliative and only temporarily slow cognitive decline, and treatments that address the underlying pathologic mechanisms of AD are completely lacking. While familial AD (FAD) is caused by autosomal dominant mutations in either amyloid precursor protein (APP) or the presenilin (PS1, PS2) genes. First, we revised 2D QSAR, 3D QSAR, CoMFA, CoMSIA and Docking of β and γ-secretase inhibitors. Next, we review 2D QSAR, 3D QSAR, CoMFA, CoMSIA and docking for GSK-3α and GSK-3β with different compound to find out the structural requirements.
Keywords: QSAR, CoMSIA, COMFA, Docking, β-secretase inhibitors, γ-secretase inhibitors, Alzheimer's disease (AD), BACE1, transmembrane, GSK-3, tyrosinase inhibitors, N-terminus
Mini-Reviews in Medicinal Chemistry
Title:Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Volume: 12 Issue: 6
Author(s): F. Prado-Prado and I. Garcia
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, Docking, β-secretase inhibitors, γ-secretase inhibitors, Alzheimer's disease (AD), BACE1, transmembrane, GSK-3, tyrosinase inhibitors, N-terminus
Abstract: Alzheimer's disease (AD) is characterized by several pathologies, this disease is a neuropathological lesion in brain. Indeed, a wealth of evidence suggests that β-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. AD is the most prevalent form of dementia, and current indications show that twenty-nine million people live with AD worldwide, a figure expected rise exponentially over the coming decades. Clearly, blocking disease progression or, in the best-case scenario, preventing AD altogether would be of benefit in both social and economic terms. However, current AD therapies are merely palliative and only temporarily slow cognitive decline, and treatments that address the underlying pathologic mechanisms of AD are completely lacking. While familial AD (FAD) is caused by autosomal dominant mutations in either amyloid precursor protein (APP) or the presenilin (PS1, PS2) genes. First, we revised 2D QSAR, 3D QSAR, CoMFA, CoMSIA and Docking of β and γ-secretase inhibitors. Next, we review 2D QSAR, 3D QSAR, CoMFA, CoMSIA and docking for GSK-3α and GSK-3β with different compound to find out the structural requirements.
Export Options
About this article
Cite this article as:
Prado-Prado F. and Garcia I., Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors, Mini-Reviews in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/138955712800493780
DOI https://dx.doi.org/10.2174/138955712800493780 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic Approach
Current Alzheimer Research Misfolded Proteins and Human Diseases
Protein & Peptide Letters Investigation of Anticholinesterase Activity of a Series of Salvia Extracts and the Constituents of Salvia staminea
The Natural Products Journal Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pleiotropic Effects of Statins in Atherosclerotic Disease: Focus on the Antioxidant Activity of Atorvastatin
Current Topics in Medicinal Chemistry Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Current Topics in Medicinal Chemistry Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research